Zydus Lifesciences Limited has received an improved ESG (Environmental, Social, and Governance) rating from a SEBI-registered rating provider, marking a positive development in the company's sustainability assessment. The pharmaceutical company disclosed this information to stock exchanges as part of its regulatory compliance obligations.

ESG Rating Details

ESG Risk Assessments and Insights Limited (ESGRAIL), a SEBI-registered ESG rating provider, has assigned an overall ESG rating to the company. The rating assessment shows year-over-year improvement in the company's ESG performance.

Independent Assessment Process

The company emphasized that it had not engaged ESGRAIL for the ESG rating assessment. ESGRAIL independently prepared the report based on publicly available information, demonstrating the provider's autonomous evaluation methodology. This independent approach ensures objectivity in the rating process without any direct company influence.

Regulatory Compliance

The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule III. The company also referenced SEBI circulars dated November 11, 2024, and December 31, 2024, as part of its regulatory framework for ESG disclosures.

Company Secretary and Compliance Officer Dhaval N. Soni signed the disclosure document on April 10, 2026, ensuring proper corporate governance procedures were followed. The disclosure was simultaneously submitted to both BSE Limited and National Stock Exchange of India Limited, maintaining transparency across all trading platforms.

Zydus Lifesciences Limited has submitted its quarterly compliance certificate to stock exchanges for the quarter ended March 31, 2026, in accordance with SEBI (Depositories and Participants) Regulations, 2018. The pharmaceutical company filed the mandatory certificate under regulation 74(5) with both BSE Limited and National Stock Exchange of India Limited on April 8, 2026.

Compliance Certificate Details

The certificate confirms that Zydus Lifesciences Limited has adhered to proper dematerialization procedures during the quarter. Key confirmations include:

Dematerialization Process Verification

The company confirmed that equity share certificates received for dematerialization during the quarter were properly processed. The certificate states that all physical certificates were mutilated and cancelled only after due verification, with the respective depository names substituted as registered owners for the dematerialized equity shares.

RTA Confirmation

MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, served as the company's registrar and transfer agent. The RTA provided confirmation that:

• Securities received from depository participants were properly confirmed to depositories
• All dematerialization procedures were completed within prescribed timelines
• Security certificates were mutilated and cancelled after due verification
• Depository names were substituted in the register of members as registered owners

Regulatory Compliance

The filing demonstrates Zydus Lifesciences' adherence to SEBI's depositories regulations, ensuring transparency in the dematerialization process. The certificate was signed by Dhaval N. Soni, Company Secretary and Compliance Officer, with membership number FCS7063.

Copies of the certificate were also submitted to National Securities Depository Limited and Central Depository Services (India) Limited, completing the regulatory filing requirements for the quarter ended March 31, 2026.